pramipexole IR / Generic mfg. - LARVOL DELTA

Dopamine agonist withdrawal syndrome - what do we really know? (PubMed, Neurol Neurochir Pol) - "Further research should focus on the natural evolution, risk factors, and duration of DAWS. Development of new generation DAs, such as tavapadon, which may reduce the side effects of dopaminergic therapy, may set new standards for treatment. Guidelines on the taper velocity of DAs, risk factors, and management therapies are to be established to improve detection and treatment of DAWS."

Journal • CNS Disorders • Depression • Fatigue • Hypotension • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry • Restless Legs Syndrome • Sleep Disorder • Suicidal Ideation

EFFECTS OF NASAL CONTINUOUS POSITIVE AIRWAY PRESSURE THERAPY IN PATIENTS WITH PARKINSON'S DISEASE (ADPD 2026) - "All of them were treated by SSNRI (maximum dose 100 mg daily) and Pramipexole (3 mg daily) during 1 month and other 8 patient (group II) by the same medicines and CPAP during the same period... Combination therapy by NCPAP and medicines, is more effective for Treatment of depression in PD patients, as well as for improvement their daily activity and motor symptoms."

Clinical • CNS Disorders • Depression • Movement Disorders • Obstructive Sleep Apnea • Parkinson's Disease • Respiratory Diseases • Sleep Disorder

PRELIMINARY DATA SUGGEST IMMUNOLOGICAL AND THERAPEUTIC POTENTIAL OF ASYN-BASED WISIT VACCINES IN HUMANS (ADPD 2026) - "A 48-year-old female diagnosed with PD 3 years earlier, with a Hoehn&Yahr stage of I and taking pramipexole, requested experimental therapy... Results obtained suggest that this new class of vaccines will yield Ab responses comparable in magnitude and target avidity to the therapeutic setting of monoclonal Abs. TRB-001 is currently being translated to a randomized, placebo-controlled, dose-finding Phase 1B study funded by the European Commission."

CNS Disorders • Movement Disorders • Parkinson's Disease

Improving Cognition in Bipolar Disorder: A Systematic Review of Current Pharmacological and Nutraceutical Approaches. (PubMed, Neuropsychobiology) - "These results suggest possible approaches for improving cognitive functioning in individuals with BD. Nevertheless, the inconsistency in outcomes and differences in study methodologies highlight the need for larger, rigorously controlled trials with uniform cognitive evaluations to confirm these findings and to assess their clinical relevance."

Journal • Review • Alzheimer's Disease • Bipolar Disorder • CNS Disorders • Cognitive Disorders • Mood Disorders • Psychiatry

Systemic medications associate with surgically treated cataract among adults over 50 years in Finland. (PubMed, Acta Ophthalmol) - "Our large nested case-control study suggests that certain systemic medications may increase the incidence of surgically treated cataract, but with the possibility of residual confounding."

Journal • Cataract • Diabetes • Metabolic Disorders • Ophthalmology

Biochemical characterization of Sapovirus 2C helicase and identification of pramipexole as a novel inhibitor in vitro. (PubMed, Bioorg Chem) - "In addition, several candidate compounds with low binding free energy to SaV-2C was identified through homology modeling and virtual screening. Among these, pramipexole (PPX) was validated as a lead inhibitor of SaV-2C ATPase function.These findings elucidate the crucial biochemical roles of SaV-2C and nominate pramipexole as a potent antiviral compound against SaV."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder

Effects of Music Therapy Combined with Hospital-Community Integrated Care on the Psychological Status of Patients with Parkinson's Disease Treated with Pramipexole and Levodopa. (PubMed, Noise Health) - "Five-element music therapy combined with hospital-community integrated care improves psychological status, alleviates clinical symptoms, enhances social adaptability and cognitive function and increases nursing satisfaction in patients with PD."

Journal • Retrospective data • CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Consensus Molecules Associated with Parkinson's Disease. (PubMed, Neurol Int) - "Drugs include L-dopa (49%), carbidopa (63%), benserazide (50%), entacapone (74%), tolcapone (56%), rasagiline (76%), selegiline (46%), pargyline (4%), ropinirole (61%), pramipexole (56%), lisuride (27%), cabergoline (16%), bromocriptine (12%), and zonisamide (9%). Adjunctive therapies include droxidopa (33%), trihexyphenidyl (28%), biperiden (17%), amantadine (24%), memantine (7%), rivastigmine (13%), donepezil (6%), galantamine (4%), domperidone (6%), clonazepam (4%), tetrabenazine (16%), mazindol (13%), quetiapine (6%), and clozapine (4%). Contraindicated drugs include haloperidol (4%), sulpiride (3%), and methyldopa (6%)...Chemical inducers of PD include 6-hydroxydopamine (40%), N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 78%), tetrahydropyridine (77%), probenecid (4%), quinolinic acid (4%), 1,2,3,4-tetrahydroisoquinoline (TIQ, 16%), salsolinol (32%), rotenone (25%), and β-Methylamino-L-alanine (BMAA, 29%). Notably, our study highlights conditional essential..."

Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy (clinicaltrials.gov) - P4 | N=24 | Active, not recruiting | Sponsor: Massachusetts General Hospital | Recruiting ➔ Active, not recruiting | Trial completion date: Nov 2025 ➔ May 2026 | Trial primary completion date: Apr 2025 ➔ Jul 2025

Enrollment closed • Trial completion date • Trial primary completion date • Genetic Disorders • Movement Disorders • Restless Legs Syndrome • Sleep Disorder

Single-dose,First-in-human of KLA478 (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Hunan Kelun Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human

Pramipexole alleviates ferroptosis in HT22 cells induced by oxygen-glucose deprivation/reoxygenation via the Nrf2/SLC7A11/GPX4 pathway. (PubMed, Sci Rep) - "Erastin recapitulated oxygen-glucose deprivation/reperfusion-induced cellular dysfunction, which was also mitigated by pramipexole. Pramipexole alleviates oxygen-glucose deprivation/reperfusion-induced neuronal damage and oxidative stress by activating the nuclear factor E2-related factor 2/solute carrier family 7 member 11/glutathione peroxidase 4 pathway to inhibit ferroptosis, highlighting its potential as a therapeutic agent for cerebral ischemia-reperfusion injury."

Journal • CNS Disorders • Movement Disorders • Reperfusion Injury • Vascular Neurology • GPX4 • SLC7A11

Restless legs syndrome treatment - gabapentinoids or dopamine agonists? (PubMed, Neurol Neurochir Pol) - "The first-line treatment options with a "strong recommendation" are now gabapentinoids (gabapentin, gabapentin enacarbil, pregabalin) along with intravenous ferric carboxymaltose...In older patients with co-morbidities in whom gabapentinoids are not well tolerated it results in relatively high rates of withdrawal. In this point of view paper, we present our personal views (supported by clinical data) on the need for both groups of medications in clinical practice because none of them is free of potential side effects and may still be useful."

Journal • Movement Disorders • Restless Legs Syndrome • Sleep Disorder

Micro pharmacokinetics-pharmacodynamics monitoring of anti-Parkinson's disease drugs using a microphysiological BBB-brain organ-on-a-chip. (PubMed, Microsyst Nanoeng) - "The pharmacokinetic profile of pramipexole (PPX) is monitored using both LC-MS and an integrated, regenerable electrochemical sensor...Furthermore, neurotransmitter (norepinephrine) exocytosis level is quantified as a pharmacodynamic indicator, enabling micro PK-PD correlation within the disease-on-a-chip model. Collectively, the proposed new method for micro PK-PD study is expected to provide great prospects for the preclinical screening and action mechanism research of novel anti-Parkinson's disease drugs."

Journal • PK/PD data • CNS Disorders • Movement Disorders • Parkinson's Disease

Pramipexole and the Risk of Serious Adverse Events (clinicaltrials.gov) - P=N/A | N=1100 | Completed | Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Adverse events • New trial • Serious adverse event • Chronic Kidney Disease • Nephrology • Renal Disease

A prospective, multicenter, double-blind, double-dummy, randomized controlled clinical study to evaluate the efficacy and safety of clonidine in the treatment of primary restless legs syndrome (RLS) (ChiCTR) - P=N/A | N=116 | Not yet recruiting | Sponsor: Shanghai General Hospital; Shanghai General Hospital

New trial • Movement Disorders • Restless Legs Syndrome • Sleep Disorder

Demographics, treatment patterns, and healthcare resource utilization in Parkinson's disease: a real-world data study using a claims database. (PubMed, Arq Neuropsiquiatr) - "The most used medications were pramipexole (45.6%), amantadine (26.0%), and entacapone (17.1%).The present study provides valuable insights into the demographic and clinical profile of PD patients in Brazil, highlighting frequent procedures and treatment patterns. A key limitation is the non-capture of basic PD medications, such as levodopa, which are often dispensed outside the analyzed datasets. These findings underscore the need for improved data integration and access to comprehensive PD care within the public health system."

HEOR • Journal • Observational data • Real-world evidence • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease

Case Report: Prolonged DAWS in an RLS patient under severe relational stress. (PubMed, Front Hum Neurosci) - "While DAWS is classically associated with high-dose dopamine agonists (DAs) in Parkinson's disease, it has also been reported in RLS patients treated with low-dose therapy (≤ 0.75 mg pramipexole equivalent), although such cases remain rare...A 6-month venlafaxine taper, completed 2 weeks before DA tapering, may have increased neurochemical vulnerability...This factor may need to be systematically assessed in DAWS management. As a rare patient-authored account, this report contributes to the understanding of DAWS in non-PD populations and highlights the need for longitudinal research to guide safer withdrawal protocols and integrated care."

Journal • CNS Disorders • Fatigue • Immunology • Movement Disorders • Pain • Parkinson's Disease • Restless Legs Syndrome • Sleep Disorder

Matsupexole: A novel nonergot dopamine receptor agonist with sustained efficacy in a rat model of Parkinson's disease and limited off-target activity. (PubMed, Br J Pharmacol) - "Matsupexole is a promising future, potentially best-in-class dopamine receptor agonist for treating PD."

Journal • Preclinical • Cardiovascular • CNS Disorders • Heart Failure • Movement Disorders • Parkinson's Disease • Sleep Disorder

Variant restless legs syndrome masquerading as refractory shoulder pain: a case report and literature review. (PubMed, Front Med (Lausanne)) - "Following targeted treatment involving iron supplements for iron deficiency anemia and pramipexole for symptomatic relief, the patient's shoulder pain and other associated symptoms improved markedly. This case expands the known clinical spectrum of variant RLS by illustrating a pain-dominant upper limb phenotype. Furthermore, we provide a summary analysis of previously reported cases of restless arms syndrome, highlighting the importance of including variant RLS in the differential diagnosis for patients presenting with unexplained shoulder or arm discomfort."

Journal • CNS Disorders • Depression • Hematological Disorders • Mood Disorders • Movement Disorders • Musculoskeletal Pain • Pain • Psychiatry • Restless Legs Syndrome • Sleep Disorder

Restless Legs Syndrome: A Review. (PubMed, JAMA) - "If possible, medications associated with RLS, including serotonergic antidepressants, dopamine antagonists, and centrally acting H1 antihistamines (eg, diphenhydramine), should be discontinued. Gabapentinoids (eg, gabapentin, gabapentin enacarbil, pregabalin) are first-line pharmacologic therapy...Dopamine agonists (eg, ropinirole, pramipexole, rotigotine) are no longer recommended as first-line medications due to the risk of augmentation, an iatrogenic worsening of RLS symptoms, which has an annual incidence of 7% to 10% with these medications. Patients who do not improve with first-line treatment or have augmented RLS often benefit from low-dose opioids (eg, methadone 5-10 mg daily)...Initial management includes cessation of exacerbating medications, as well as iron supplementation for patients with low-normal iron indices. If medication therapy is indicated, gabapentinoids are first-line treatment."

Clinical • Journal • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Coronary Artery Disease • Depression • Diabetic Neuropathy • Heart Failure • Hematological Disorders • Movement Disorders • Multiple Sclerosis • Nephrology • Pain • Parkinson's Disease • Psychiatry • Renal Disease • Restless Legs Syndrome • Sleep Disorder • Suicidal Ideation

Dopamine dysfunction beyond psychosis: Reevaluating its role in depression, anxiety, and obsessive-compulsive disorder. (PubMed, Psychiatr Danub) - "Dopaminergic agents (e.g., bupropion, pramipexole, aripiprazole), neuromodulatory approaches (e.g., TMS, DBS), and biomarker-guided interventions showed promise, particularly in treatment-resistant or subtype-specific presentations. Dopamine dysfunction is a core, transdiagnostic mechanism in depression, anxiety, and OCD, affecting key circuits involved in reward, motivation, and cognitive control. Integrating dopaminergic biomarkers and interventions into psychiatric care may facilitate personalised treatment and improve clinical outcomes."

Journal • Review • CNS Disorders • Depression • Inflammation • Major Depressive Disorder • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry

Vertebrobasilar dolichoectasia compresses midbrain, worsens Parkinson symptoms, and evokes Holmes tremor: A case report. (PubMed, Medicine (Baltimore)) - "In patients with both PD and HT, the identification of underlying causes and the proper symptomatic treatment are crucial for relieving the symptoms. However, the ultimate approaches would be microvascular decompression, deep-brain stimulation, or stereotactic thalamotomy."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Two novel variants of VPS13C gene related Parkinsonism: A case report and literature review. (PubMed, Medicine (Baltimore)) - "This study identifies 2 novel pathogenic variants in VPS13C, expanding the known mutational spectrum of the gene. Additionally, brain MRI may serve as a potential imaging marker for disease progression. A review of the literature indicates that VPS13C-related Parkinsonism appears as a heterogeneous disorder, including PD and dementia with Lewy bodies. VPS13C mutations are highly diverse, with point mutations being the most common, followed by splice-site variants. Genetic screening is essential for an accurate diagnosis and distinction between different forms of early onset PD. This increases clinicians' understanding of the clinical and genetic characteristics of VPS13C-related Parkinsonism."

Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Lewy Body Disease • Movement Disorders • Parkinson's Disease • VPS13C

Electrospun poly (vinyl alcohol)/zein-based nanofibrous dressings co-loaded with pramipexole and hesperidin for diabetic wound management: In silico, in vitro, and in vivo assessments. (PubMed, Int J Biol Macromol) - "ELISA showed decreased MMP-9 and TNF-α, as well as increased VEGF, by day 8. Therefore, it was shown that PRA-HES bilayer scaffold has anti-inflammatory, antioxidant and pro-angiogenic actions, and is a cost-effective option for diabetic wound care."

Journal • Preclinical • Diabetes • Inflammation • Metabolic Disorders • MMP9 • TNFA

Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment) (clinicaltrials.gov) - P=N/A | N=167 | Completed | Sponsor: Stanford University | Enrolling by invitation ➔ Completed

Trial completion • CNS Disorders • Depression • Mood Disorders • Psychiatry